Allakos
Yahoo Finance • last year
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a bus... Full story
Yahoo Finance • last year
Allakos Appoints Neil Graham to its Board of Directors
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allerg... Full story
Yahoo Finance • last year
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib – – AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation– SAN CARLOS, Calif., June 12,... Full story
Yahoo Finance • 2 years ago
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
Allakos (NASDAQ: ALLK) finished the trading week in style, with its stock price climbing by just under 9% on Friday. The prognosticator getting notably more bullish on Allakos was Jefferies' Maury Raycroft, who upped his recommendation on... Full story
Yahoo Finance • 2 years ago
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a busi... Full story
Yahoo Finance • 2 years ago
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a bu... Full story
Yahoo Finance • 2 years ago
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 – – AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity... Full story
Yahoo Finance • 2 years ago
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells – – AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 – – Mo... Full story
Yahoo Finance • 2 years ago
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirent... Full story
Yahoo Finance • 2 years ago
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced... Full story
Yahoo Finance • 2 years ago
Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a... Full story
Yahoo Finance • 3 years ago
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided... Full story
